Novelix Pharmaceuticals Ltd

As of June 30, 2026, Novelix Pharmaceuticals Ltd carries a market capitalization of 1.83B, placing it among publicly traded companies globally. Its enterprise value stands at 1.83B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Novelix Pharmaceuticals Ltd has 23.90M shares outstanding.

As of June 30, 2026, Novelix Pharmaceuticals Ltd trades at a trailing price-to-earnings ratio of 40.58.

As of June 30, 2026, Novelix Pharmaceuticals Ltd trades at an EV/EBITDA multiple of 39.81 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.24 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 41.25 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 1.83B versus a market cap of 1.83B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 73.43M in revenue per employee across its workforce of 20.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Novelix Pharmaceuticals Ltd recorded 7.22M in income tax expense. That works out to an effective tax rate of 16.59, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 43.50M, leaving 36.28M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Novelix Pharmaceuticals Ltd's stock has gained approximately 32.37% over the past 52 weeks. The 50-day moving average sits at 73.75, while the 200-day moving average is 65.01.

Over the twelve months ended June 30, 2026, Novelix Pharmaceuticals Ltd generated 1.47B in revenue and converted that into 36.28M in net income, yielding earnings per share of 1.89. EBITDA reached 45.92M, while operating income came in at 44.32M.

Over the twelve months ended June 30, 2026, Novelix Pharmaceuticals Ltd posted a gross margin of 4.81, reflecting its pricing power and cost economics. The operating margin of 3.02 and net profit margin of 2.47 provide insight into operational efficiency.

Novelix Pharmaceuticals Ltd's most recent stock split took place on October 4, 2010 with a 10:1 split ratio.